市場調査レポート

商品コード

1417603

子宮がんの世界市場の評価：タイプ別、モダリティ別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Uterine Cancer Market Assessment, By Types, By Modality, By End-users, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年01月29日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 230 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 705,420円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 893,532円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,285,432円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の子宮がんの市場規模は、2023年に260億5,000万米ドル、2031年に386億3,000万米ドルに達し、2024年～2031年の予測期間にCAGRで5.05%の成長が見込まれています。世界の子宮がん市場は、多くの市場促進要因の影響を受けています。その要因は、子宮がんの有病率の上昇、スクリーニングと診断の技術の進歩、研究への注目の高まり、新たな治療アプローチ、意識向上と教育への重点的な取り組み、高齢化の影響、政府主導のプログラムや政策などです。

子宮がんの罹患率の増加は、世界の子宮がん市場の大きな成長促進要因となっています。この動向は、肥満、ライフスタイルの変化、老年人口の増加などの要因によるところが大きいです。診断される患者の数が増え続けているため、効果的なスクリーニング、診断、治療オプションに対する需要が高まっています。スクリーニングと診断技術の進歩は、早期発見において極めて重要な役割を果たし、患者の予後改善に寄与します。超音波、MRI、低侵襲技術などのモダリティは、子宮がんの診断と治療の方法に革命をもたらし、医療従事者が疾患を早期に発見することを可能にしています。標的療法、免疫療法、精密医療などの新しいアプローチが人気を集めています。

閉経後の女性は特に脆弱であるため、高齢者の増加は子宮がんのリスクの増大に寄与しています。世界の子宮がん市場を形成する上で、政府の取り組みや政策は不可欠です。これには、研究への資金援助、医療サービスへのアクセス、包括的ながん治療プログラムの開発などが含まれます。臨床試験や進行中の科学研究は、革新的な治療オプションや治療法の発見に不可欠です。患者支援団体は影響力を行使し、認知度を高め、支援を提供し、ケアと治療へのアクセス強化を提唱しています。彼らの活動は、患者が総合的なケアを受け、医療を超えたサポートを受けられる環境作りに寄与しています。

子宮がんの有病率の上昇

子宮がんの有病率の増加は、世界の子宮がん市場を牽引する極めて重要な役割を果たしています。BMC Women's Healthによると、2020年現在、世界中で新たに子宮がんと診断された患者数は41万7,000人と推定され、厄介な上昇傾向が明らかになっています。2022年に、米国で6万5,000人以上の子宮内膜がん患者が診断されました。注目すべきは、40歳未満の女性における子宮がんの発生率が倍増していることであり、若年層に対するより効率的なスクリーニングと治療の選択肢が不可欠であることを強調しています。米国では、子宮がんは2023年に新規患者の中で4番目に多いがんとなり、女性のがん関連死因の第6位になると予測されています。子宮がんの罹患率と死亡率の上昇に対処するためには、継続的な研究、診断ツールの改善、先駆的な治療法の進歩が急務であることが浮き彫りになっています。早期発見、啓発キャンペーン、治療法の進化における精力的な取り組みは、この公衆衛生上の課題に効果的に対処する上で極めて重大な要素です。

研究への注目の高まり

世界の子宮がん市場の成長は、革新的な治療法に焦点を当てた研究開発への投資の増加によって大きく後押しされています。こうした投資は、患者の転帰と生活の質を改善する新治療法の発見と開発を促進します。研究活動は、標的療法や免疫療法を含む治療オプションの拡大に寄与し、子宮がん患者に新たな希望をもたらします。さらに、研究がより効果的な治療法を発見することで、製薬企業やバイオテクノロジー企業がこれらの治療法の開発に投資することを促し、市場の成長を促進し、最終的には子宮がん患者の予後を向上させます。

2023年10月、ミズーリ大学医学部で助教授を務めるTae Hoon Kim博士は、多額の助成金を受け取っています。この5年間の助成金は総額226万米ドルで、国立衛生研究所の一部門であるEunice Kennedy Shriver National Institute of Child Health and Human Developmentから授与されました。Kim博士の研究プロジェクトは、子宮内膜過形成に罹患している生殖年齢の女性の受胎可能性を維持することを目的とした治療法の調査に焦点を当てています。

当レポートでは、世界の子宮がん市場について調査分析し、市場規模と予測、市場力学、主要企業情勢と見通しなどを提供しています。

市場規模と予測
- 金額
- 数量
タイプ別
- 子宮内膜腺がん
- 漿液性腺がん
- 乳頭漿液性がん
- 子宮肉腫
- その他
モダリティ別
- 診断
- 治療
エンドユーザー別
- 病院
- 外来手術センター
- 専門クリニック
- 薬局
- その他
地域別
- 北米
- 欧州
- 南米
- アジア太平洋
- 中東・アフリカ
市場シェア：企業別（2023年）

第5章世界の子宮がん市場の見通し：地域別（2017年～2031年）

北米
- 市場規模と予測
- タイプ別
- モダリティ別
- エンドユーザー別
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- イタリア
- 英国
- ロシア
- オランダ
- スペイン
- トルコ
- ポーランド
南米
- ブラジル
- アルゼンチン
アジア太平洋
- インド
- 中国
- 日本
- オーストラリア
- ベトナム
- 韓国
- インドネシア
- フィリピン
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- 南アフリカ

第6章市場マッピング（2023年）

タイプ別
段階別
グループ別
モダリティ別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需給分析
輸出入の分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第9章規制枠組みとイノベーション

臨床試験
特許情勢
規制当局の承認
イノベーション/新技術

第10章主要企業情勢

マーケットリーダー上位5社の競合マトリクス
マーケットリーダー上位5社の市場収益分析（2023年）
合併と買収/合弁事業（該当する場合）
SWOT分析（市場参入企業5社）
特許分析（該当する場合）

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

Novartis AG
Bristol-Myers Squibb Company
Merck & Co., Inc.
Pfizer, Inc.
AstraZeneca plc
Johnson & Johnson Innovative Medicine
Bayer AG
AbbVie Inc.
GSK plc
Eli Lilly and Company

第14章戦略的推奨事項

第15章当社について、免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 2. Global Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 3. Global Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 4. Global Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 5. Global Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 6. Global Uterine Cancer Market Share (%), By Region, 2017-2031F
Figure 7. North America Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 8. North America Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 9. North America Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 10. North America Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 11. North America Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 12. North America Uterine Cancer Market Share (%), By Country, 2017-2031F
Figure 13. United States Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 14. United States Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 15. United States Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 16. United States Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 17. United States Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 18. Canada Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 19. Canada Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 20. Canada Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 21. Canada Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 22. Canada Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 23. Mexico Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 24. Mexico Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 25. Mexico Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 26. Mexico Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 27. Mexico Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 28. Europe Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 29. Europe Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 30. Europe Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 31. Europe Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 32. Europe Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 33. Europe Uterine Cancer Market Share (%), By Country, 2017-2031F
Figure 34. Germany Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 35. Germany Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 36. Germany Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 37. Germany Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 38. Germany Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 39. France Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 40. France Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 41. France Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 42. France Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 43. France Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 44. Italy Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 45. Italy Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 46. Italy Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 47. Italy Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 48. Italy Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 49. United Kingdom Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 50. United Kingdom Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 51. United Kingdom Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 52. United Kingdom Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 53. United Kingdom Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 54. Russia Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 55. Russia Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 56. Russia Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 57. Russia Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 58. Russia Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 59. Netherlands Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 60. Netherlands Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 61. Netherlands Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 62. Netherlands Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 63. Netherlands Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 64. Spain Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 65. Spain Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 66. Spain Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 67. Spain Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 68. Spain Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 69. Turkey Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 70. Turkey Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 71. Turkey Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 72. Turkey Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 73. Turkey Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 74. Poland Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 75. Poland Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 76. Poland Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 77. Poland Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 78. Poland Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 79. South America Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 80. South America Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 81. South America Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 82. South America Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 83. South America Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 84. South America Uterine Cancer Market Share (%), By Country, 2017-2031F
Figure 85. Brazil Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 86. Brazil Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 87. Brazil Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 88. Brazil Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 89. Brazil Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 90. Argentina Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 91. Argentina Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 92. Argentina Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 93. Argentina Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 94. Argentina Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 95. Asia-Pacific Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 96. Asia-Pacific Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 97. Asia-Pacific Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 98. Asia-Pacific Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 99. Asia-Pacific Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 100. Asia-Pacific Uterine Cancer Market Share (%), By Country, 2017-2031F
Figure 101. India Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 102. India Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 103. India Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 104. India Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 105. India Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 106. China Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 107. China Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 108. China Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 109. China Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 110. China Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 111. Japan Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 112. Japan Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 113. Japan Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 114. Japan Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 115. Japan Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 116. Australia Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 117. Australia Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 118. Australia Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 119. Australia Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 120. Australia Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 121. Vietnam Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 122. Vietnam Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 123. Vietnam Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 124. Vietnam Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 125. Vietnam Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 126. South Korea Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 127. South Korea Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 128. South Korea Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 129. South Korea Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 130. South Korea Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 131. Indonesia Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 132. Indonesia Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 133. Indonesia Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 134. Indonesia Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 135. Indonesia Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 136. Philippines Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 137. Philippines Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 138. Philippines Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 139. Philippines Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 140. Philippines Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 141. Middle East & Africa Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 142. Middle East & Africa Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 143. Middle East & Africa Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 144. Middle East & Africa Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 145. Middle East & Africa Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 146. Middle East & Africa Uterine Cancer Market Share (%), By Country, 2017-2031F
Figure 147. Saudi Arabia Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 148. Saudi Arabia Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 149. Saudi Arabia Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 150. Saudi Arabia Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 151. Saudi Arabia Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 152. UAE Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 153. UAE Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 154. UAE Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 155. UAE Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 156. UAE Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 157. South Africa Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 158. South Africa Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
Figure 159. South Africa Uterine Cancer Market Share (%), By Types, 2017-2031F
Figure 160. South Africa Uterine Cancer Market Share (%), By Modality, 2017-2031F
Figure 161. South Africa Uterine Cancer Market Share (%), By End-users, 2017-2031F
Figure 162. By Types Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163. By Modality Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164. By End-users Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX10897

Global uterine cancer market size was valued at USD 26.05 billion in 2023, expected to reach USD 38.63 billion in 2031, with a CAGR of 5.05% for the forecast period between 2024 and 2031. The global uterine cancer market is subject to a multitude of factors that are driving the market. The contributing factors consist of rising prevalence of uterine cancer, advancements in screening and diagnostic technologies, increased focus on research, novel treatment approaches, focused initiatives on awareness and education, impact of aging population, and government-led programs and policies.

The increasing incidence of uterine cancer stands as a prominent driver for the growth of global uterine cancer market. The trend is largely attributed to factors like obesity, lifestyle changes, and rising aging population. As the number of diagnosed patients continues to rise, there is a growing demand for effective screening, diagnostic, and treatment options. Advancements in screening and diagnostic technologies play a pivotal role in early detection, aiding in better patient outcomes. Modalities such as ultrasound, MRI, and minimally invasive techniques have revolutionized the way uterine cancer is diagnosed and treated, enabling healthcare professionals to detect the disease at early stages. Novel approaches such as targeted therapies, immunotherapies, and precision medicine are gaining popularity.

Growing geriatric is contributing to the increased risk of uterine cancer, as postmenopausal women are particularly vulnerable. Government initiatives and policies are integral in shaping the global uterine cancer market. These include funding for research, access to healthcare services, and the development of comprehensive cancer care programs. Clinical trials and ongoing scientific research are essential for uncovering innovative treatment options and therapies. Patient advocacy groups exert influence, raising awareness, providing support, and advocating for enhanced care and treatment access. Their efforts contribute to an environment where patients receive comprehensive care and support beyond medical treatment.

Rising Prevalence of Uterine Cancer

The increasing prevalence of uterine cancer plays a pivotal role in driving the global uterine cancer market. According to BMC Women's Health, as of 2020, there were an estimated 417,000 new uterine cancer diagnoses worldwide, revealing a troubling upward pattern. In 2022, more than 65,000 endometrial cancer patients were diagnosed in the United States. Notably, the incidence of uterine cancer has doubled among women under the age of 40, underscoring the essential need for more efficient screening and treatment options for the younger demographic. In the United States, uterine cancer is anticipated to rank as the fourth most common cancer among new cases and the sixth leading cause of female cancer-related deaths in 2023. It highlights the urgent demand for ongoing research, improved diagnostic tools, and the advancement of pioneering therapies to address the rise in uterine cancer incidence and mortality rates. Vigorous efforts in early detection, awareness campaigns, and the evolution of treatment modalities are crucial components in effectively addressing this public health challenge.

Growing Focus on Research

The growth of the global uterine cancer market is significantly propelled by increasing investments in research and development efforts focused on innovative treatments. These investments drive the discovery and development of novel therapies, which can improve patient outcomes and quality of life. Research initiatives contribute to expanding treatment options, including targeted therapies and immunotherapies, offering new hope for uterine cancer patients. Furthermore, as research uncovers more effective treatments, it encourages pharmaceutical and biotechnology companies to invest in the development of these therapies, fostering market growth and ultimately enhancing the prognosis for those affected by uterine cancer.

In October 2023, Dr. Tae Hoon Kim, PhD, who serves as an assistant professor at the University of Missouri School of Medicine, received a substantial grant. The five-year grant, totaling USD 2.26 million, was awarded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health. Dr. Kim's research project focuses on investigating treatments aimed at preserving fertility in women of reproductive age who are affected by endometrial hyperplasia.

Government Initiatives

Governments globally are implementing initiatives to raise awareness about uterine cancer, recognizing its significance in public health. By promoting education and regular screenings, these campaigns aim to reduce the stigma associated with uterine cancer and encourage early detection. As awareness grows, more women are likely to seek timely medical attention, driving the demand for diagnostic and treatment services. It in turn, contributes to the expansion of global uterine cancer market, as healthcare providers and pharmaceutical companies respond to the increased demand, ultimately improving outcomes for patients through early intervention and effective treatments. In June 2023, Israel and other countries attended Endometrial Cancer Awareness Week to combat the lack of awareness among women and the insufficient funding allocated for the diagnosis and treatment of the condition.

Immunotherapy is Expected to Witness Significant Growth Over the Forecasted Period

The global uterine cancer market is witnessing a substantial uptick in the utilization of immunotherapy as a preferred treatment modality. Immunotherapy, a therapeutic approach that leverages the body's immune system to target and eliminate cancer cells, has displayed encouraging outcomes in the context of uterine cancer treatment. The growing demand for immunotherapy is primarily rooted in its potential to offer more effective and less invasive treatment alternatives, especially for cases at advanced or recurrent stages. Consequently, both pharmaceutical companies and research institutions are investing in the development of tailored immunotherapeutic agents for uterine cancer. The growing interest in immunotherapy stands as an important catalyst in the expansion of the global uterine cancer market.

In May 2023, the addition of Imfinzi plus Lynparza and Imfinzi alone resulted in notable enhancements in progression-free survival for individuals with advanced endometrial cancer when incorporated with chemotherapy. DUO-E marks the inaugural global Phase III trial where the combination of immunotherapy and PARP inhibition showcased substantial clinical advantages within this context.

Development of Novel Treatment Methods for High-Risk Uterine Cancer

High-risk uterine cancer typically presents with factors like advanced stage, aggressive histology, or recurring tumors, making it a formidable challenge for patients and healthcare providers. The increasing incidence of high-risk uterine cancer underscores the critical need for effective therapeutic interventions, including advanced surgical techniques, radiation therapy, targeted therapies, and immunotherapies. As these treatment options evolve and become more accessible, the growing demand to address high-risk uterine cancer becomes a driving force in the global healthcare market.

As an example, in February 2023, GSK plc disclosed that the US Food and Drug Administration (FDA) had issued complete approval for Jemperli (dostarlimab-gxly). The approval pertains to the treatment of adult patients dealing with recurrent or advanced endometrial cancer, specifically those characterized by a mismatch repair-deficiency (dMMR) as determined through an FDA-sanctioned test. These patients must have experienced disease progression after prior treatment with a platinum-based regimen in any therapeutic context who are not considered suitable candidates for curative surgical procedures or radiation therapy.

Future Market Scenario

The future of the global uterine cancer market looks promising, contributing to its overall growth. Several factors are driving growth in the market. Ongoing advancements in medical research and technology are continually expanding our understanding of uterine cancer, leading to the development of more targeted and effective treatment options. Increasing awareness and early detection efforts will likely reduce late-stage diagnoses, improving treatment outcomes. Additionally, the rising incidence of uterine cancer, driven by factors such as an aging population and lifestyle changes, creates a sustained demand for healthcare services. Furthermore, the emergence of innovative therapies, including immunotherapies and precision medicine, offers new avenues for treatment, giving hope to patients with limited options. The factors collectively ensure a promising trajectory for the global uterine cancer market, where research, innovation, and awareness campaigns converge to enhance patient care and drive market growth.

Key Players Landscape and Outlook

The global uterine cancer market is witnessing significant growth due to strategic collaborations among major pharmaceutical companies. These partnerships bring expertise, resources, and research capabilities together from multiple organizations to accelerate the development of innovative therapies and treatment approaches. The collaborations facilitate the combination of knowledge and technologies, resulting in faster drug discovery and development. They enable a more efficient response to the complex challenges posed by uterine cancer, ultimately benefiting patients by expanding treatment options and improving outcomes. The synergy among pharmaceutical companies spurs innovation and drives market expansion, meeting the growing demand for effective uterine cancer treatments.

In June 2022, Astellas and Sutro Biopharma revealed a global strategic partnership aimed at advancing innovative immunostimulatory antibody-drug conjugates (iADCs) for the treatment of uterine cancer. iADCs represents a cutting-edge therapeutic approach in uterine cancer treatment.

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Uterine Cancer Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. Value
- 4.1.2. Volume
4.2. By Types
- 4.2.1. Endometroid Adenocarcinoma
- 4.2.2. Serous Adenocarcinoma
- 4.2.3. Papillary Serous Carcinoma
- 4.2.4. Uterine Sarcoma
- 4.2.5. Others
4.3. By Modality
- 4.3.1. Diagnosis
  - 4.3.1.1. CT scan
  - 4.3.1.2. MRI Scan
  - 4.3.1.3. PET Scan
  - 4.3.1.4. Blood Test
  - 4.3.1.5. Ultrasound
  - 4.3.1.6. Endometrial Biopsy
- 4.3.2. Treatment
  - 4.3.2.1. Surgery
  - 4.3.2.2. Radiation Therapy
  - 4.3.2.3. Chemotherapy
  - 4.3.2.4. Immunotherapy
  - 4.3.2.5. Others
4.4. By End-users
- 4.4.1. Hospitals
- 4.4.2. Ambulatory Surgical Centers
- 4.4.3. Specialty Clinics
- 4.4.4. Pharmacies
- 4.4.5. Others
4.5. By Region
- 4.5.1. North America
- 4.5.2. Europe
- 4.5.3. South America
- 4.5.4. Asia-Pacific
- 4.5.5. Middle East and Africa
4.6. By Company Market Share (%), 2023

5. Global Uterine Cancer Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. Value
  - 5.1.1.2. Volume
- 5.1.2. By Types
  - 5.1.2.1. Endometroid Adenocarcinoma
  - 5.1.2.2. Serous Adenocarcinoma
  - 5.1.2.3. Papillary Serous Carcinoma
  - 5.1.2.4. Uterine Sarcoma
  - 5.1.2.5. Others
- 5.1.3. By Modality
  - 5.1.3.1. Diagnosis
  - 5.1.3.1.1. CT scan
  - 5.1.3.1.2. MRI Scan
  - 5.1.3.1.3. PET Scan
  - 5.1.3.1.4. Blood Test
  - 5.1.3.1.5. Ultrasound
  - 5.1.3.1.6. Endometrial Biopsy
  - 5.1.3.2. Treatment
  - 5.1.3.2.1. Surgery
  - 5.1.3.2.2. Radiation Therapy
  - 5.1.3.2.3. Chemotherapy
  - 5.1.3.2.4. Immunotherapy
  - 5.1.3.2.5. Others
- 5.1.4. By End-users
  - 5.1.4.1. Hospitals
  - 5.1.4.2. Ambulatory Surgical Centers
  - 5.1.4.3. Specialty Clinics
  - 5.1.4.4. Pharmacies
  - 5.1.4.5. Others
- 5.1.5. United States*
  - 5.1.5.1. Market Size & Forecast
  - 5.1.5.1.1. Value
  - 5.1.5.1.2. Volume
  - 5.1.5.2. By Types
  - 5.1.5.2.1. Endometroid Adenocarcinoma
  - 5.1.5.2.2. Serous Adenocarcinoma
  - 5.1.5.2.3. Papillary Serous Carcinoma
  - 5.1.5.2.4. Uterine Sarcoma
  - 5.1.5.2.5. Others
  - 5.1.5.3. By Modality
  - 5.1.5.3.1. Diagnosis
  - 5.1.5.3.1.1. CT scan
  - 5.1.5.3.1.2. MRI Scan
  - 5.1.5.3.1.3. PET Scan
  - 5.1.5.3.1.4. Blood Test
  - 5.1.5.3.1.5. Ultrasound
  - 5.1.5.3.1.6. Endometrial Biopsy
  - 5.1.5.3.2. Treatment
  - 5.1.5.3.2.1. Surgery
  - 5.1.5.3.2.2. Radiation Therapy
  - 5.1.5.3.2.3. Chemotherapy
  - 5.1.5.3.2.4. Immunotherapy
  - 5.1.5.3.2.5. Others
  - 5.1.5.4. By End-users
  - 5.1.5.4.1. Hospitals
  - 5.1.5.4.2. Ambulatory Surgical Centers
  - 5.1.5.4.3. Specialty Clinics
  - 5.1.5.4.4. Pharmacies
  - 5.1.5.4.5. Others
- 5.1.6. Canada
- 5.1.7. Mexico

All segments will be provided for all regions and countries covered:

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3. South America
- 5.3.1. Brazil
- 5.3.2. Argentina
5.4. Asia-Pacific
- 5.4.1. India
- 5.4.2. China
- 5.4.3. Japan
- 5.4.4. Australia
- 5.4.5. Vietnam
- 5.4.6. South Korea
- 5.4.7. Indonesia
- 5.4.8. Philippines
5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Types
6.2. By Stages
6.3. By Group
6.4. By Modality
6.5. By End-users
6.6. By Region

7. Macro Environment and Industry Structure

7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. Novartis AG
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
13.2. Bristol-Myers Squibb Company
13.3. Merck & Co., Inc.
13.4. Pfizer, Inc.
13.5. AstraZeneca plc
13.6. Johnson & Johnson Innovative Medicine
13.7. Bayer AG
13.8. AbbVie Inc.
13.9. GSK plc
13.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

子宮がんの世界市場の評価：タイプ別、モダリティ別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Uterine Cancer Market Assessment, By Types, By Modality, By End-users, By Region, Opportunities and Forecast, 2017-2031F

子宮がんの有病率の上昇

研究への注目の高まり

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の子宮がん市場の見通し（2017年～2031年）

第5章 世界の子宮がん市場の見通し：地域別（2017年～2031年）

第6章 市場マッピング（2023年）

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制枠組みとイノベーション

第10章 主要企業情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的推奨事項

第15章 当社について、免責事項